Please assess the completion status of the following clinical trial:

Trial Title: A Study in the Treatment of Acute Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bipolar I disorder and currently display an acute manic or mixed episode (with or without psychotic features)~* Patients must have a Y-MRS total score of greater or equal to 20 at visit 2~* Patients must have experienced at least one manic or mixed episode prior to study enrollment~* Female of childbearing potential must be using a medically accepted means of contraception, or practice sexual abstinence~* Each patient must have a level of understanding sufficient to communicate intelligently with study personnel~* Patients must be considered reliable~* Each patient must understand the nature of the study and signed informed consent~Exclusion Criteria:~* Female patients who are pregnant or lactating~* Serious, unstable illnesses such that hospitalization for the disease is anticipated within 3 month or death is anticipated within 3 years~* Uncorrected hypothyroidism or hyperthyroidism~* Narrow-angle glaucoma~* History of allergic reactions or intolerance to study medications~* DSM-IV substance dependence within the past 30 days at the judgement of the investigator~* Judged clinically to be at serious suicidal risk~* Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to visit 2~* Any patient treated with clozapine within 4 weeks prior to visit 2~* Subjects who have received treatment with ECT within one month prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Patients will be given olanzapine
- B (Type: ACTIVE_COMPARATOR): Patients will be given either haloperidol or zuclopentixol

Based on this trial design, predict the completion outcome and termination type (if applicable).